{"pageProps":{"initialStudiesData":{"page":{"totalFilteredElements":65},"studies":[{"active":true,"description":"

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma

","eudractNumber":"2023-510178-15","id":10012,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-10-23T10:03:29+02:00","shortTitle":"CA073-1020 GOLSEEK-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"CAELUM Cardiac Amyloid Reaching for Extended Survival A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
","eudractNumber":"2019-004254-28","id":6946,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT04504825","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-26T11:02:10+02:00","shortTitle":"CAEL101-301","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
","eudractNumber":"2024-520154-38","id":10760,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-01-20T10:27:50+01:00","shortTitle":"CAMELOT - 2 75276617 AML3001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and \nDexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,  Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell \nTransplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are \nTransplant Eligible","eudractNumber":"2021-003284-10","id":9102,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05257083","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T11:08:47+02:00","shortTitle":"CARTITUDE-6, EMN28/68284528MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL): CLL-16 STUDIE DER DCLLSG","eudractNumber":"2020-004360-26","id":8660,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"del (Deletions)","id":"mt_247"},{"name":"del (17p)","id":"mt_23"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT05197192","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-10-25T14:28:21+02:00","shortTitle":"CLL16","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \nadjustment of treatment duration to improve outcomes","eudractNumber":"2023-510294-34","id":11270,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-08-11T11:42:59+02:00","shortTitle":"CLL18 / MOIRAI-TRIAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Wirksamkeit und Sicherheit von Carfilzomib in Kombination mit Ibrutinib oder Ibrutinib alleine bei Patienten mit Morbus Waldenström (CZAR-1)","eudractNumber":"2018-003526-88","id":7449,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"},{"name":"CXCR4 (C-X-C chemokine receptor type 4)","id":"mt_177"}],"nctNumber":"NCT04263480","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-04-28T11:27:47+02:00","shortTitle":"CZAR-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung","eudractNumber":"2018-003691-12","id":5573,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[{"name":"Mismatch Repair Deficiency (dMMR)","id":"mt_270"},{"name":"MSI (Mikrosatelitteninstabilität)","id":"mt_51"},{"name":"MSI-H","id":"mt_52"}],"nctNumber":"NCT04089631","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2020-08-07T08:25:33+02:00","shortTitle":"Circulate AIO-KRK-0217","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
","eudractNumber":"2024-515008-38-00","id":11262,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"PD-1 (Programmed cell death protein 1)","id":"mt_43"},{"name":"PD-L1","id":"mt_25"}],"nctNumber":"NCT06627647","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-07-08T08:46:54+02:00","shortTitle":"D702FC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"DESTINY-Biliary\nTract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and\nRilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab\nfor First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract\nCancer","eudractNumber":"2023-508057-19-00","id":10413,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"HER2/neu","id":"mt_19"},{"name":"HER2-","id":"mt_285"}],"nctNumber":"NCT06467357","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-04-14T10:14:48+02:00","shortTitle":"DESTINY-BTC 01 D781PC00001","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]}]},"initialUrl":"/api/studies?lang=de&page=2&pfs=ph_9&size=10","jsonDlt":"{\"name\":\"Studien des CCC Mainfranken\",\"numberOfItems\":10,\"itemListElement\":[{\"position\":1,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the \\nEfficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP \\nChemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma

\",\"name\":\"CA073-1020 GOLSEEK-1\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10012\"}},{\"position\":2,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"CAELUM Cardiac Amyloid Reaching for Extended Survival A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
\",\"name\":\"CAEL101-301\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/6946\"}},{\"position\":3,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy
\",\"name\":\"CAMELOT - 2 75276617 AML3001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10760\"}},{\"position\":4,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and \\nDexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab,  Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell \\nTransplant (ASCT) in Participants with Newly Diagnosed Multiple Myeloma who are \\nTransplant Eligible\",\"name\":\"CARTITUDE-6, EMN28/68284528MMY3005\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/9102\"}},{\"position\":5,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"EINE PROSPEKTIVE, OFFENE, MULTIZENTRISCHE, RANDOMISIERTE PHASE-3-STUDIE MIT ACALABRUTINIB, OBINUTUZUMAB UND VENETOCLAX (GAVE) IM VERGLEICH ZU OBINUTUZUMAB UND VENETOCLAX (GVE) BEI ZUVOR UNBEHANDELTEN PATIENTEN MIT HOCHRISIKO (17P-DELETION, TP53-MUTATION ODER KOMPLEXEM KARYOTYP) CHRONISCHER LYMPHATISCHER LEUKÄMIE (CLL): CLL-16 STUDIE DER DCLLSG\",\"name\":\"CLL16\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/8660\"}},{\"position\":6,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ \\nsmall lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for \\nadjustment of treatment duration to improve outcomes\",\"name\":\"CLL18 / MOIRAI-TRIAL\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11270\"}},{\"position\":7,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Wirksamkeit und Sicherheit von Carfilzomib in Kombination mit Ibrutinib oder Ibrutinib alleine bei Patienten mit Morbus Waldenström (CZAR-1)\",\"name\":\"CZAR-1\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/7449\"}},{\"position\":8,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung\",\"name\":\"Circulate AIO-KRK-0217\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/5573\"}},{\"position\":9,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
\",\"name\":\"D702FC00001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/11262\"}},{\"position\":10,\"item\":{\"@context\":\"https://schema.org/\",\"@type\":\"Course\",\"description\":\"DESTINY-Biliary\\nTract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and\\nRilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab\\nfor First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract\\nCancer\",\"name\":\"DESTINY-BTC 01 D781PC00001\",\"provider\":{\"@type\":\"Organization\",\"name\":\"Comprehensive Cancer Center Mainfranken\",\"sameAs\":\"https://cccmf-studien-homepage.vercel.app\"},\"url\":\"https://cccmf-studien-homepage.vercel.app/studies/10413\"}}],\"url\":\"https://cccmf-studien-homepage.vercel.app/studies?page=3&pfs=ph_9\"}","__lang":"de","__namespaces":{"common":{"app_title":"Comprehensive Cancer Center Mainfranken Studiendatenbank","app_description":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","app_version":"Version","central_contacts":"Ihre Ansprechpartnerin im CCC MF","email_label":"E-Mail","contact_info_email":"anmeldung_ccc@ukw.de","contact_info_email_title":"E-Mail der Anmeldung des Comprehensive Cancer Center Mainfranken","fax_label":"Fax","contact_info_fax_number":"+49 931 201-35359","contact_info_fax_number_title":"Faxnummer des Comprehensive Cancer Center Mainfranken","phone_label":"Tel.","contact_info_phone_number":"+49 931 201-35350","contact_info_phone_number_title":"Telefonnummer des Comprehensive Cancer Center Mainfranken","website_label":"Webseite","contact_info_website":"https://www.med.uni-wuerzburg.de/ccc/startseite/","contact_info_website_title":"Webseite des Comprehensive Cancer Center Mainfranken","comprehensive_cancer_center_mainfranken_cccmf":"Comprehensice Cancer Centers Mainfranken (CCC MF)","profile_picture_alt_text":"Foto von {{ name }}","close_menu_title":"Studienfilter ausblenden","open_menu_title":"Studienfilter einblenden","search_button_label":"Suchen","text_field_search_label":"Suche...","text_field_clear_buton_title":"Textfeld leeren","hide_filter_button_text":"Filter ausblenden","show_filter_button_text":"Filtern","back_url_title":"Zurück","imprint":"Impressum","data_protection":"Datenschutz","accessibility":"Barrierefreiheit","studies_list_breadcrumb_label":"Studienliste","tree_view_check_boxes_number_of_studies":"{{numberOfStudies}} Treffer, wenn dieser Filter aktiviert wird","footer_logo_ccc_title":"Zur Webseite des CCC Mainfranken","footer_logo_ozw_title":"Zur Webseite des Onkologischen Zentrums Würzburg","footer_logo_ukw_title":"Zur Webseite des Universitätsklinikums Würzburg","footer_logo_isz_ectu_title":"Zur Webseite des Interdisziplinären Studienzentrums mit ECTU","loading":"Laden...","landing_page_name":"Startseite","theme_dark":"Hell","theme_light":"Dunkel","study_status_active":"Rekrutierung läuft","study_status_inactive":"Rekrutierung beendet"},"filters":{"includeinactive":"Nicht rekrutierende Studien auch anzeigen","indications":"Nach Erkrankungen filtern","isonly":"Nur Therapiestudien anzeigen","therapy_lines":"Nach Therapielinien filtern","mutations":"Nach molekularen Markern filtern","organizations":"Nach studienaktiven Standorten filtern","phases":"Nach Phasen filtern","reset_filter":"Filter zurücksetzen","filters_selected_alert_message":"Filter aktiv","reset_all_filters":"Filter zurücksetzen","close_filters_menu":"Zurück zu den Suchergebnissen"},"home":{"banner_alt":"Logo des Comprehensive Cancer Center Mainfranken","logo_alt":"Logo des Comprehensive Cancer Center Mainfranken","subtitle":"Übersicht der klinisch-onkologischen Studien im CCC MF Netzwerk","title":"CCC MF Studiendatenbank"},"paginatedList":{"number_of_items_found_text":"Seite {{page}} - Studien {{start}} bis {{end}} von insgesamt {{total}}","no_items_found":"Es wurden keine Einträge gefunden.","pagination_item_aria_label_current_page":"Aktuelle Seite, Seite {{page}}","pagination_item_aria_label_page":"Zu Seite {{page}} navigieren","pagination_item_aria_label_next_page":"Zur nächsten Seite, Seite {{page}} navigieren","pagination_item_aria_label_previous_page":"Zur vorherigen Seite, Seite {{page}} navigieren"},"studiesList":{"alert_text":"Hier finden Sie grundlegende Angaben zu klinischen Studien des ","button_aria_label_details":"Zu den Details der Studie {{shortTitle}}","button_label_details":"Mehr Informationen","indications":"Indikationen","mutations":"Molekulare Marker"}}},"__N_SSP":true}